Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · CARLSMED, INC. (CARL)

Carlsmed Q2 revenue rises 57% to $18.9 million; raises 2026 revenue guidance

Mixed Impact 4 of 5 earnings Written later

Carlsmed reported second quarter 2026 revenue of $18.9 million, up 57% from a year earlier, and raised its full-year 2026 revenue guidance to $74 million to $78 million from $72 million to $77 million. Its net loss widened to $10.5 million from $6.8 million, so higher sales came with larger losses for shareholders.

Key points

  • Q2 2026 revenue was $18.9 million, up from $12.1 million in Q2 2025.
  • Net loss was $10.5 million, compared with $6.8 million a year earlier; gross margin rose to 76.8% from 73.4%.
  • Full-year 2026 revenue guidance raised to $74 million to $78 million from $72 million to $77 million.
  • Cash, restricted cash, short-term investments and marketable securities totaled $89.3 million as of June 30, 2026.

The filing

CompanyCARLSMED, INC. (CARL)
Form8-K, current report
Filed with the SECAug 5, 2026, 4:05 PM ET
Accession number0001794546-26-000015

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.